Update shared on31 Jul 2025
Fair value Increased 3.90%Globe Life’s consensus analyst price target increased modestly, reflecting slightly improved valuation sentiment as both the discount rate and future P/E remained virtually unchanged, resulting in a new target of $156.91.
What's in the News
- SEC has concluded its investigation and does not intend to recommend enforcement action against Globe Life.
- Company reaffirmed 2025 net operating income guidance of $14.25 to $14.65 per diluted share.
- Repurchased 1.9 million shares (2.29%) for $226 million in Q2 2025; buyback program is 97.13% complete.
- Removed from the Russell 1000 Dynamic Index.
- Pledged $450,000 to Sandhills Global Youth Complex, supporting an accessible sports facility for youth with disabilities.
Valuation Changes
Summary of Valuation Changes for Globe Life
- The Consensus Analyst Price Target has risen slightly from $153.73 to $156.91.
- The Discount Rate for Globe Life remained effectively unchanged, moving only marginally from 6.47% to 6.44%.
- The Future P/E for Globe Life remained effectively unchanged, moving only marginally from 9.77x to 9.81x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.